NEVERMINED-AG
12.7.2022 15:02:09 CEST | Business Wire | Press release
Nevermined AG , a Web3 company that provides tools to read, write and own your digital assets, announced their initial investment round of €3 million, co-led by Signature Ventures and Polymorphic Capital. The Nevermined platform consists of modular solutions that easily allow users the ability to create and monetize digital assets and participate in the read-write-own vision of Web3.
The platform offers the foundations for building digital ecosystems with components like Tokenization Engine, Marketplace Creator, Royalties Engine, Decentralized Access Control, DAO Framework and DISC, or Data In-Situ Computation, for Remote Computation.
Nevermined CEO Don Gossen shares, “The best internet is the one that everyone can access and own. And this is what Nevermined allows people to do. When it comes to Data mixed with Web3 our pedigree speaks for itself – our team has been working with cutting-edge tech for over 20 years, first in Big Data, and now in Web3. With these building blocks, we can help you realize your vision. I’d argue we’re the best team in the world that does what we do.”
According to a new report by Grand View Research , the global blockchain technology market size is expected to reach $1,431 billion by 2030. With this market opportunity and its solid, proven technology, Nevermined will leverage this capital raise to:
Be more complete and scalable by advancing its product roadmap: Nevermined will enhance its digital asset development platform that makes Web3 accessible by streamlining the creation, monetization and management of decentralized digital assets. Some key projects include:
- Enterprise: A global energy company used the platform to create a peer-to-peer carbon certificate trading marketplace.
- Creative: Autonomies is using Nevermined to build a music NFT platform and DAO, allowing for fairer value distribution between musicians, labels and collectors.
- Science: In a world first, VitaDAO used Nevermined to tokenize the IP of scientific research, conducted by the Scheibye-Knudsen Lab in Copenhagen.
Be more accessible by accelerating global footprint: To foster company growth and better customer experience, Nevermined will be strengthening its presence in key areas including product, engineering, marketing and community.
Be easier to use by expanding the breadth and depth of the partner ecosystem: Nevermined will establish both technical and creative partnerships that will bolster its mission. Along with deepening partnerships with initiatives such as Autonomies , a music NFT platform allowing artists to become stakeholders.
“We only invest in outstanding teams that build the backbone of the decentralized future,'' said Managing Director Juliane Hahn, Signature. “We see many startups that try to combine Data with Blockchains. Nevermined is the first company that understands the complexities and provides actual solutions at the intersection of Data and Web3. In the future every data-driven company will require the ability to turn their data silos into data ecosystems. Nevermined delivers the full product stack to do just that.”
“We’ve been very impressed with the Nevermined team,” said Vitaly Spassky, founder of Polymorphic Capital. “They have the vision, as well as the tech talent and pedigree to execute. To us digital assets are a crucial building block for the decentralized web. And the Nevermined platform makes it super easy for teams and projects to integrate Web3 tech. We’re very excited to see what people will build with Nevermined.”
Nevermined began as an incubation project within Keyko AG to solve issues around data sharing using tokenization and smart contract gateways. From there it evolved from a data-centric solution to a decentralized digital assets solution with much broader applicability.
About Nevermined
Nevermined is a Web3 company that provides tools to read, write and own your digital assets, founded by CEO Don Gossen, CTO Aitor Argomaniz and CIO Dimitri De Jonghe. They met while creating Ocean Protocol, the world’s first decentralized data marketplace. In 2019, they founded Keyko over a shared belief in the power of digital ecosystems. They helped a variety of organizations develop Web3 ecosystems, worth a combined value of $3 billion. In 2022, they decided to spin out Nevermined as a standalone technology platform.
More info on https://nevermined.io/
About Signature Ventures
Signature Ventures is an early-stage Venture Capital fund investing in Blockchain, Distributed Ledger Technology and Web3 technology. Based in Germany, the fund invests in Pre-Seed to Series A, globally with a focus on Europe. Signature Ventures is managed by Juliane Hahn, Founding Partner, and Dr. Georg Stricker, Tech Partner. They combine an extensive track record of VC investments with deep Blockchain expertise.
About Polymorphic Capital
Polymorphic Capital is a venture capital firm that invests globally in teams creating the future of the internet with decentralized protocols and digital assets. They specialize in infrastructure, finance and gaming.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom